Search

Background: Research has demonstrated that parent-child attachment security and school connectedness (SC) are protective factors against substance use, depression, and suicidality during adolescence. However, past research has examined these factors independently, and little is known about how attachment security and SC work in conjunction to reduce risk. Objective: The present study examined the moderating role of SC on the relations between parent-adolescent attachment (security, anxiety, and avoidance) and substance use, depression, and suicidality among at-risk adolescents. Method: Using a cross-sectional design, 480 community-based adolescents (60.5% female; M[subscript age] = 14.86) aged 12-18 years self-reported parent-adolescent attachment, adolescent substance use, depression, and suicidality. Results: High levels of attachment security in conjunction with high SC predicted the lowest risk for adolescent substance use. Several sex differences were found: SC significantly moderated the relation between attachment security and depressive symptoms in female adolescents and suicidality in male adolescents. Results also revealed that the moderating of role of SC differed in relation to attachment anxiety versus attachment avoidance for female versus male adolescents. Conclusion: Findings point to the importance of testing associations between multiple dimensions of attachment and SC on several well-established mental health outcomes in a sample of high-risk adolescents.

Aims and Objective: In recent period, basal cell markers high molecular weight cytokeratin (HMWCK), P63 and prostate biomarker AMACR have been used as adjuvant to morphology in diagnostically challenging cases with a very high sensitivity and specificity. Materials and Methods: In this prospective study, total of 80 cases including 40 cases of malignant lesions and 40 cases of benign lesions of the prostate were taken. Tumor grade was determined according to Gleason's grading system. AMACR, HMWCK, P63 expressions were determined by immunohistochemical staining. Results: This study showed AMACR had a sensitivity of 90%, specificity of 100%. AMACR was not expressed in any of the 40 cases of benign lesions of the prostate while in malignant lesions of prostate it was expressed in 36 of 40 (90%) cases; 15 of 16 (93%) of well-differentiated carcinoma were positive for AMACR expression; 17 of 19 (89.47%) moderately differentiated and 4 of 5 (80%) cases of poorly differentiated tumors were positive for AMACR. There was statistically significant difference in expression of AMACR between benign and malignant lesions of the prostate (P = 0.001). In benign lesions, HMWCK and P63 were expressed in all the 40 (100%) cases, while in malignant lesions of prostate it was not expressed in any of the (0%) case. AMACR expression was not seen in any of the benign lesion. Out of 40 malignant cases, 4 cases were negative for AMACR, HMWCK and P63, 36 cases were positive only for AMACR, but no case was positive for HMWCK and P63. Conclusions: As an adjunct to biopsy, AMACR, HMWCK and P63 have potential for combating diagnostically challenging cases.

Context: A new indigenous recombinant human chorionic gonadotropin (r-hCG) has been developed in India with a comparable pharmacological profile to that of Ovitrelle® (Merck Serono). Aims: This study aims to compare the efficacy and safety of the new r-hCG with that of Ovitrelle for induction of ovulation in women undergoing intrauterine insemination (IUI). Settings and Design: Randomized (2:1), multicenter, open-label, equivalence clinical trial conducted in India. Subjects and Methods: A total of 217 women, aged 20–37 years, undergoing IUI were administered the new r-hCG (test) 250 mcg or Ovitrelle 250 mcg (comparator) after ovarian stimulation with gonadotropins. The ovulation rate was compared as the primary outcome. In addition, pregnancy rates, incidence of adverse events (AEs), and development of immunogenicity were assessed. Statistical Analysis Used: The ovulation and pregnancy rates were compared using Chi-squared test with statistical significance at P < 0.05. Results: With 144 women in the test group and 73 in the comparator group, the ovulation rate (85.4% vs. 78.1%; P = 0.17) and pregnancy rate (serum β hCG test) (11.8% vs. 12.3%; P = 0.91) were similar in both groups. A total of 15 AEs were reported (11 in the test r-hCG group and 4 in the comparator group) in 11 women; none of these were serious, and all were judged to be unrelated to the study drug. No subject developed immunogenic reaction to the test drug. Conclusions: The new preparation of r-hCG was equivalent to the conventional preparation of r-HCG in the induction of ovulation in patients undergoing IUI.

Uterine leiomyoma is a benign smooth muscle neoplasm, typically arising in uterus and deep soft tissue. In the present case, tumour size of 7×4×3 cm identified on subserosal aspect of uterus. Grossly, tumour was well circumscribed, whitish nodule and on cut surface whitish whirls were seen. Microscopic examination showed a cellular spindle cell population with numerous eosinophilic amianthoid-like fibers. Immunohistochemically, the tumour showed positivity for H-caldesmon, desmin, alpha smooth-muscle actin, and negativity for CD10. The finding of amianthoid-like fibers in leiomyoma is very rare. Amianthoid fibers are hyalinized collagen mats. It extends the histomorphological spectrum of leiomyomas. Amianthoid fibers are very characteristics of “intra nodal palisaded myofibroblastoma”. Presence of “Amianthoid-like fibers” creates histomorphologically similar picture between leiomyoma and “intra nodal palisaded myofibroblastoma”. Pathologist should be aware of such variant of leiomyoma that contains “Amianthoid-like fibers” to avoid confusion with other tumours.